CAMBRIDGE, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the pri
Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and Decreases in Mutant Z-AAT in Circulation Across I
BEAM incurs a narrower-than-expected loss in the fourth quarter. The company remains focused on pipeline development.
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $1.10. This compares to earnings of $1.73 per share a year ago.
Enrollment Target for Adult Sickle Cell Disease Patients Achieved in BEACON Trial of BEAM-101; Dosing of 30 Patients and Updated Data Expected by Mid-2025 Initial Data from Phase 1/2 Trial of BEAM-302
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that man
The average of price targets set by Wall Street analysts indicates a potential upside of 67.3% in Beam Therapeutics (BEAM). While the effectiveness of this highly sought-after metric is questionable,
Here is how Beam Therapeutics Inc. (BEAM) and Aurora Cannabis Inc. (ACB) have performed compared to their sector so far this year.
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Joh
The average of price targets set by Wall Street analysts indicates a potential upside of 84.5% in Beam Therapeutics (BEAM). While the effectiveness of this highly sought-after metric is questionable,
Here, we discuss some reasons why investing in BEAM stock now may turn out to be a prudent move.
CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the comp
Beam Therapeutics (BEAM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
More Than 40 Adult Sickle Cell Disease Patients Now Enrolled in BEACON Trial of BEAM-101; Beam Expects to Dose 30 Patients and Present Updated Data by Mid-2025
Beam Therapeutics (BEAM) Gene editing firm Beam Therapeutics is developing its own pipeline with base editing as its foundation technology, a technique that changes a single DNA or RNA base without cu
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE